top of page
xavier-mouton-photographie-MRWHSKimBJk-u

Welcome to 

Venn Therapeutics

LEADING THE EFFORT IN CLINICAL TRANSLATION

A fundamental shift has taken place in our understanding of TGF-β biology which has significant implications for how we treat TGF-β-driven diseases. 

Venn Therapeutics is a precision medicine company.  We are developing a pipeline of novel, best-in-class agents that precisely target key mechanisms of fibrosis and NASH.

FIRST-IN-CLASS

Integrin-mediated activation of TGF-β is at the root of resistance to therapies in the cancer tumor micro-environment, fibrosis, and NASH.

With our lead asset being 

blockade.png
mi-pham-FtZL0r4DZYk-unsplash_edited_edit

A WORLD WITHOUT CANCER

Our mission is to contribute to a world without cancer.

Our goal is to become the preeminent oncology franchise for pharmaceutical companies seeking the most promising advances in immuno-oncology, and to contribute to making that vision a reality.

C6D4 called VTX-001. Cryo-EM Reveals Integrin-Mediated TGF-b Activation without Release from Latent TGF-b, Nishimura et.al

bottom of page